Leu, M.; Riebeling, T.; Dröge, L.H.; Hubert, L.; Guhlich, M.; Wolff, H.A.; Brockmöller, J.; Gaedcke, J.; Rieken, S.; Schirmer, M.A.
8-Oxoguanine DNA Glycosylase (OGG1) Cys326 Variant: Increased Risk for Worse Outcome of Patients with Locally Advanced Rectal Cancer after Multimodal Therapy. Cancers 2021, 13, 2805.
https://doi.org/10.3390/cancers13112805
AMA Style
Leu M, Riebeling T, Dröge LH, Hubert L, Guhlich M, Wolff HA, Brockmöller J, Gaedcke J, Rieken S, Schirmer MA.
8-Oxoguanine DNA Glycosylase (OGG1) Cys326 Variant: Increased Risk for Worse Outcome of Patients with Locally Advanced Rectal Cancer after Multimodal Therapy. Cancers. 2021; 13(11):2805.
https://doi.org/10.3390/cancers13112805
Chicago/Turabian Style
Leu, Martin, Theresa Riebeling, Leif Hendrik Dröge, Laura Hubert, Manuel Guhlich, Hendrik Andreas Wolff, Jürgen Brockmöller, Jochen Gaedcke, Stefan Rieken, and Markus Anton Schirmer.
2021. "8-Oxoguanine DNA Glycosylase (OGG1) Cys326 Variant: Increased Risk for Worse Outcome of Patients with Locally Advanced Rectal Cancer after Multimodal Therapy" Cancers 13, no. 11: 2805.
https://doi.org/10.3390/cancers13112805
APA Style
Leu, M., Riebeling, T., Dröge, L. H., Hubert, L., Guhlich, M., Wolff, H. A., Brockmöller, J., Gaedcke, J., Rieken, S., & Schirmer, M. A.
(2021). 8-Oxoguanine DNA Glycosylase (OGG1) Cys326 Variant: Increased Risk for Worse Outcome of Patients with Locally Advanced Rectal Cancer after Multimodal Therapy. Cancers, 13(11), 2805.
https://doi.org/10.3390/cancers13112805